Executive record

Svetlana N. Makhni

Chief Financial Officer at Prime Medicine, Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:svetlana-n-makhniVersion: public-0As of: 2026-09-28

Not yet claimed6 published Claims2 sources
  • Executive

Key Claims

Biography

Ms. Makhni has served as Chief Financial Officer since April 2026, previously serving as CFO of Marengo Therapeutics and Escient Pharmaceuticals, and earlier holding investment banking roles at BMO Capital Markets, Goldman Sachs, Westbrook Partners, and The Blackstone Group. She holds an M.B.A. from Harvard Business School and a B.S. from the Wharton School of the University of Pennsylvania.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Executive career

  1. Current · dates not publishedChief Financial Officer · Prime Medicine, Inc.
  2. 2026 to end not publishedExecutive title: Chief Financial Officer · Organization not publishedPRME DEF 14A executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. PRME DEF 14A executive officers

    sec filing · Source published: Apr 23, 2026 · Retrieved: May 5, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 5, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 5, 2026
    • Executive company: Executive at Prime Medicine, Inc. · Claim reviewed: May 5, 2026
    • Executive title: Executive title: Chief Financial Officer · Claim reviewed: May 5, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 5, 2026

  2. Open source

    sec def 14a · Source published: Apr 23, 2026 · Retrieved: Sep 12, 2026

    Supports 1 claim
    • Professional Role: Chief Financial Officer at Prime Medicine, Inc. · Claim reviewed: Sep 12, 2026